- Home
- BSM vs TARS Comparison
BSM vs TARS Comparison
Compare BSM & TARS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | BSM | TARS |
|---|---|---|
| Founded | 1876 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Medicinal Chemicals and Botanical Products |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.1B | 2.8B |
| IPO Year | 2015 | 2020 |
Fundamental Metrics
Financial Performance| Metric | BSM | TARS |
|---|---|---|
| Price | $15.13 | $77.03 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 9 |
| Target Price | $13.00 | ★ $80.56 |
| AVG Volume (30 Days) | 410.1K | ★ 608.8K |
| Earning Date | 05-27-2026 | 06-01-2026 |
| Dividend Yield | ★ 8.03% | N/A |
| EPS Growth | N/A | ★ 48.21 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $469,919,000.00 | $451,360,000.00 |
| Revenue This Year | $17.23 | $51.34 |
| Revenue Next Year | $9.86 | $29.34 |
| P/E Ratio | $12.82 | ★ N/A |
| Revenue Growth | 8.35 | ★ 146.71 |
| 52 Week Low | $11.90 | $38.51 |
| 52 Week High | $15.52 | $85.25 |
Technical Indicators
Market Signals| Indicator | BSM | TARS |
|---|---|---|
| Relative Strength Index (RSI) | 55.00 | 61.33 |
| Support Level | $14.54 | $63.36 |
| Resistance Level | $15.25 | $78.41 |
| Average True Range (ATR) | 0.31 | 3.87 |
| MACD | -0.04 | 1.56 |
| Stochastic Oscillator | 59.08 | 78.70 |
Price Performance
Historical ComparisonAbout BSM Black Stone Minerals L.P.
Black Stone Minerals LP is an oil and natural gas mineral company. It owns oil and natural gas mineral interests, which makes up the majority of its asset base. Its business is actively managing an existing portfolio of mineral and royalty assets to maximize its value and expanding asset base through acquisitions of additional mineral and royalty interests.
About TARS Tarsus Pharmaceuticals Inc.
Tarsus Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the development and commercialization of therapeutics, starting with eye care. The company is focused on the development and commercialization of first-in-class therapeutic candidates to provide treatment for ophthalmic conditions. The company's candidate XDEMVY is a novel investigational eye drop to treat blepharitis caused by the infestation of Demodex mites, referred to as Demodex blepharitis.